Thursday, April 08, 2021 10:53:07 AM
“Our proprietary technologies and methods employ magnetic nanoparticles targeted toward cells associated with cancer and other diseases and provide the ability to detect these cells using highly sensitive magnetic sensors. We are in collaboration with Global Cancer Technology and their scientists to explore their very promising drug delivery technology. We envision a nanotechnology platform that would deliver both our proprietary imaging capabilities along with the targeted therapeutic capabilities that GCT provides. With a successful collaboration physicians, for the first time, would be able to image and treat a tumor using a single nanotechnology delivery medium.”
Robert Prouix
President & CEO, Imagion Biosystems Inc
Recent MHTX News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/19/2024 05:18:10 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/15/2024 09:04:11 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 07:12:38 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM